Meditope Biosciences Overview

  • Founded
  • 2011

Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 1

Meditope Biosciences General Information

Description

Developer of cancer therapeutics systems intended to reduce the off-target effects of therapeutic antibodies. The company offers an innovative platform with advanced features, including precision targeting of tumor cells, enhanced immune response modulation, and personalized treatment approaches, enabling doctors to improve the lives of patients and their families with potentially more efficacious, safer, and cost-efficient antibody-based products.

Contact Information

Website
www.meditope.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Drug Discovery
Primary Office
  • 301 North Lake Avenue
  • Suite 900
  • Pasadena, CA 91105
  • United States
+1 (800) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Meditope Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Secondary Transaction - Private 01-Dec-2022 00.000 Completed Startup
3. Accelerator/Incubator 01-Jan-2018 00.000 Completed Startup
2. Early Stage VC (Series A1) 07-Oct-2015 $2.02M $5.62M Completed Startup
1. Early Stage VC (Series A) 01-May-2013 $3.6M $3.6M Completed Startup
To view Meditope Biosciences’s complete valuation and funding history, request access »

Meditope Biosciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of cancer therapeutics systems intended to reduce the off-target effects of therapeutic antibodies. The compan
Biotechnology
Pasadena, CA
6 As of 2023
00.000
00000000000 00.000

000000

dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt u
0000 000000000
Basel, Switzerland
00 As of 0000
00000
0000 0000-00-00
00000000000 00000

000000

liqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi u
0000 000000000
Basel, Switzerland
00 As of 0000
00000
0000 0000-00-00
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Meditope Biosciences Competitors (52)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Anaveon Venture Capital-Backed Basel, Switzerland 00 00000 00000000000 00000
0000000 Venture Capital-Backed Basel, Switzerland 00 00000 00000000000 00000
000000000 00000000 Formerly VC-backed Salt Lake City, UT 000 00.000 000000000 00.000
00000 00000000 Venture Capital-Backed South San Francisco, CA 00 00000 00000000000 00000
00000 000000000000 Venture Capital-Backed Berkeley, CA 00 000.00 00000000000 000.00
You’re viewing 5 of 52 competitors. Get the full list »

Meditope Biosciences Patents

  • 14

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 1

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

Meditope Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2017215350-A1 Anti-egfr antibody drug conjugate Inactive 02-Feb-2016 00000000000
CA-3012196-A1 Anti-egfr antibody drug conjugate Pending 02-Feb-2016 00000000000
EP-3411382-A4 Anti-egfr antibody drug conjugate Pending 02-Feb-2016 00000000000 0
EP-3411382-A1 Anti-egfr antibody drug conjugate Pending 02-Feb-2016 00000000
JP-2019513690-A Anti-egfr antibody drug conjugate Pending 02-Feb-2016 A61K47/6849 0
To view Meditope Biosciences’s complete patent history, request access »

Meditope Biosciences Executive Team (5)

Name Title Board Seat Contact Info
Michael Hsieh Chief Financial Officer
David Stover Ph.D Chief Scientific Officer and Board Member
Robert McKenzie Executive Vice President, Business Development & Board Member
Martin Latterich Ph.D Chief Executive Officer, President and Board Member
You’re viewing 4 of 5 executive team members. Get the full list »

Meditope Biosciences Board Members (8)

Name Representing Role Since
David Stover Ph.D Meditope Biosciences Chief Scientific Officer and Board Member 000 0000
George Prendergast Self Board Member 000 0000
Heng Wei Chang Meditope Biosciences Board Member 000 0000
Martin Latterich Ph.D Self Chief Executive Officer, President and Board Member 000 0000
Michael Goldberg Meditope Biosciences Chairman 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Meditope Biosciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Meditope Biosciences Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Springboard Enterprises Accelerator/Incubator Minority 000 0000 000000 0
To view Meditope Biosciences’s complete investors history, request access »

Ready to get started?

Request a free trial